MultiHance 用於 CNS (腦部) 顯影之相關文獻

Kushnirsky M, Nguyen V, Katz JS, Steinklein J, Rosen L, Warshall C, Schulder M, Knisely JP.

Time-delayed contrast-enhanced MRI improves detection of brain metastases and apparent treatment volumes.

J Neurosurg. 2015 Sep 11:1-7 

http://www.ncbi.nlm.nih.gov/pubmed/26361281

 

 

Schneider G, Schürholz H, Kirchin MA, Bücker A, Fries P. Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance) in children. Pediatr Radiol. 2013 Jan;43(2):202-11.

www.ncbi.nlm.nih.gov/pubmed/23179483

 

Li ZL, Chen X, Xia CC, Sun JY, Li CX, Tang HH, Song B. [Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Jul;43(4):601-4.

www.ncbi.nlm.nih.gov/pubmed/22997905

 

Seidl Z1, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, Pasowicz M, Yeung R, Paraniak-Gieszczyk B, Yemen B, Anzalone N, Citterio A, Schneider G, Bastianello S, Ruscalleda J. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012 Jun;33(6):1050-8. doi: 10.3174/ajnr.A3033. Epub 2012 Mar 1.

www.ncbi.nlm.nih.gov/pubmed/22383237

 

Achenbach M1, Figiel JH, Burbelko M, Heverhagen JT. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging. 2010 Nov;32(5):1166-71.

www.ncbi.nlm.nih.gov/pubmed/21031523 

 

Rumboldt Z, Rowley HA, Steinberg F, Maldjian JA, Ruscalleda J, Gustafsson L, Bastianello S. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla. J Magn Reson Imaging. 2009 Apr;29(4):760-7.

www.ncbi.nlm.nih.gov/pubmed/19306364

 

Rowley HA1, Scialfa G, Gao PY, Maldjian JA, Hassell D, Kuhn MJ, Wippold FJ 2nd, Gallucci M, Bowen BC, Schmalfuss IM, Ruscalleda J, Bastianello S, Colosimo C. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008 Oct;29(9):1684-91. doi: 10.3174/ajnr.A1185. Epub 2008 Jul 3

www.ncbi.nlm.nih.gov/pubmed/18599575

 

Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Weber M, Stadlbauer A, Grabner G, Knosp E, Trattnig S. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology. 2008 Jan;50(1):9-16. Epub 2007 Sep 18.

www.ncbi.nlm.nih.gov/pubmed/17876570

 

Kuhn MJ, Picozzi P, Maldjian JA, Schmalfuss IM, Maravilla KR, Bowen BC, Wippold FJ 2nd, Runge VM, Knopp MV, Wolansky LJ, Gustafsson L, Essig M, Anzalone N. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg. 2007 Apr;106(4):557-66.

www.ncbi.nlm.nih.gov/pubmed/17432704

 

Maravilla KR. Gadobenate dimeglumine-enhanced MR imaging of patients with CNS diseases. Eur Radiol. 2006 Nov;16 Suppl 7:M8-15.

www.ncbi.nlm.nih.gov/pubmed/18655262

 

Maravilla KR, Maldjian JA, Schmalfuss IM, Kuhn MJ, Bowen BC, Wippold FJ 2nd, Runge VM, Knopp MV, Kremer S, Wolansky LJ, Anzalone N, Essig M, Gustafsson L. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006 Aug;240(2):389-400.

www.ncbi.nlm.nih.gov/pubmed/16801373

 

Essig M. Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.

www.ncbi.nlm.nih.gov/pubmed/18655261

 

Essig M. MR imaging of CNS tumors: are all contrast agents created the same? Neuroradiology. 2006 Apr;48 Suppl 1:3-8.

www.ncbi.nlm.nih.gov/pubmed/16699847

 

Essig M. Gadobenate dimeglumine (MultiHance) in MR imaging of the CNS: studies to assess the benefits of a high relaxivity contrast agent. Acad Radiol. 2005 May;12 Suppl 1:S23-7

www.ncbi.nlm.nih.gov/pubmed/16106542

 

Colosimo C, Knopp MV, Barreau X, Gérardin E, Kirchin MA, Guézénoc F, Lodemann KP. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology. 2004 Aug;46(8):655-65

www.ncbi.nlm.nih.gov/pubmed/15205859

 

Knopp MV, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, Moeller A, Seeberg AH, Lodemann KP. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2004 Jan;230(1):55-64.

www.ncbi.nlm.nih.gov/pubmed/14695387

 

Essig M. Clinical experience with MultiHance in CNS imaging. Eur Radiol. 2003 Nov;13 Suppl 3:N3-10.

www.ncbi.nlm.nih.gov/pubmed/15015875

 

Runge VM, Armstrong MR, Barr RG, Berger BL, Czervionke LF, Gonzalez CF, Halford HH, Kanal E, Kuhn MJ, Levin JM, Low RN, Tanenbaum LN, Wang AM, Wong W, Yuh WT, Zoarski GH. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol. 2001 Feb;36(2):65-71.

www.ncbi.nlm.nih.gov/pubmed/11224753

 

 

聯絡我們

普樂可醫藥股份有限公司 地址 : 台北市民生東路一段58號11樓 電話 : (02) 2521-0566
傳真 : (02) 2571-0157
p5418173@ms17.hinet.net